logo

CAMP

CAMP4 Therapeutics·NASDAQ
--
--(--)
--
--(--)
5.18 / 10
Netural

Camp4 Therapeutics' fundamental profile is mixed with several red flags. The Current assets turnover ratio and Fixed assets turnover ratio are below par, indicating inefficiency in asset utilization. Although Revenue-MV and Profit-MV are favorable, the overall fundamental score of 5.2/10 earns only a 'Neutral' rating, implying that investors should wait for clearer operational momentum before committing capital.

Fundamental(5.18)SentimentTechnical

Analysis Checks(7/10)

Revenue-MV
Value-2.78
Score2/3
Weight16.50%
1M Return11.31%
Inventory turnover ratio
Value47.88
Score3/3
Weight7.44%
1M Return5.89%
Gross profit margin (%)
Value100.00
Score3/3
Weight16.48%
1M Return11.05%
Profit-MV
Value0.47
Score2/3
Weight11.37%
1M Return7.95%
Net income-Revenue
Value-0.15
Score2/3
Weight11.53%
1M Return8.04%
PB-ROE
Value-0.35
Score0/3
Weight5.83%
1M Return4.05%
Current assets turnover ratio
Value0.04
Score0/3
Weight-2.64%
1M Return-2.30%
Fixed assets turnover ratio
Value0.93
Score1/3
Weight-1.50%
1M Return-1.34%
Asset-MV
Value-0.51
Score3/3
Weight23.71%
1M Return14.63%
Cash-MV
Value-0.07
Score2/3
Weight11.27%
1M Return7.78%
Is CAMP fundamentally strong?
  • CAMP scores 5.18/10 on fundamentals and holds a Fair valuation at present. Backed by its -65.87% ROE, -1404.47% net margin, -3.73 P/E ratio, 3.40 P/B ratio, and 159.69% earnings growth, these metrics solidify its Netural investment rating.